


natureOUTLOOK

PRECISION MEDICINE

8 September 2016 / Vol 537 / Issue No 7619



Cover art: Andrew Baker

Editorial

Herb Brody, Michelle Grayson, Nick Haines, Richard Hodson, Jenny Rooke

Art & Design

Wesley Fernandes
Mohamed Ashour
Andrea Duffy

Production

Matthew Carey
Ian Pope
Karl Smart

Sponsorship

David Bagshaw,
Samantha Morley

Marketing

Nicole Jackson

Project Manager

Anastasia Panoutsou

Art Director

Kelly Buckheit Krause

Publisher

Richard Hughes

Editorial Director,

Partnership Media

Stephen Pincock

Chief Magazine Editor

Rosie Mestel

Editor-in-Chief

Philip Campbell

The underlying concept of precision medicine, in which health care is individually tailored on the basis of a person's genes, lifestyle and environment, is not new: transfusion patients have been matched with donors according to blood type for more than a century (see page S52). But advances in genetics, and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality.

Since the first human genome was sequenced in 2001, after more than a decade and at a cost of around US\$3 billion, the technology has become much faster and cheaper. Many genomes can now be sequenced in a single day for around \$1,000 each (S54). As a result, genome sequencing is entering medical practice, particularly to diagnose rare disorders, where conventional techniques have failed (S64).

On the treatment front, despite a series of setbacks, several gene therapies are edging closer to approval (S57). A few medical centres are pioneering pharmacogenetics, using an individual's genome to prescribe the safest, most effective drug for them, and are developing the infrastructure needed to make it work in a clinical setting (S60). But some researchers argue that more evidence of benefit is required first (S63).

Precision medicine is powered by patient data. The health records and genetic codes of patients and healthy volunteers are vital, and help people to influence their own health care and the direction of research (S66). Securing participants' trust is crucial to the success of large-scale programmes such as the US National Institutes of Health's Precision Medicine Initiative (S69). But this is hard when the promised anonymity is revealed to be little more than a fig leaf (S70).

We are pleased to acknowledge the financial support of Illumina, Inc. in producing this Outlook. As always, *Nature* has sole responsibility for all editorial content.

Richard Hodson
Supplements editor

CONTENTS

S52 TIMELINE

Medical histories

Individualized treatments are not new

S54 TECHNOLOGY

Read the instructions

The rise of fast, cheap DNA sequencing

S57 GENE THERAPY

Industrial strength

Biotech companies seek approval

S60 PHARMACOGENETICS

The right drug for you

Can our genetics improve prescribing?

S63 PERSPECTIVE

The precision-oncology illusion

Vinay Prasad argues that the evidence does not stack up

S64 DIAGNOSIS

A clear answer

Baffling symptoms can be resolved

S66 PARTICIPATION

Power to the patients

The importance of building trust

S69 Q&A

Precision medicine goes megascale

Kathy Hudson explains how the Precision Medicine Initiative works

S70 PRIVACY

The myth of anonymity

Your genomic data may not be secure

RELATED ARTICLES

S73 Archibald E. Garrod: the father of precision medicine

Robert L. Perlman & Diddahally R. Govindaraju

S75 The promise and peril of genomic screening in the general population

Michael C. Adams et al.

S82 Unpatients—why patients should own their medical data

Leonard J. Kish & Eric J. Topol

S86 Correspondence

Jorge L. Contreras et al.

S89 Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions

O. Alagoz, D. Durham & K. Kasirajan

Nature Outlooks are sponsored supplements that aim to stimulate interest and debate around a subject of interest to the sponsor, while satisfying the editorial values of *Nature* and our readers' expectations. The boundaries of sponsor involvement are clearly delineated in the *Nature Outlook* Editorial guidelines available at go.nature.com/e4dwzw

CITING THE OUTLOOK

Cite as a supplement to *Nature*, for example, *Nature* Vol. XXX, No. XXXX Suppl., Sxx–Sxx (2016).

VISIT THE OUTLOOK ONLINE

The *Nature Outlook Precision Medicine* supplement can be found at <http://www.nature.com/nature/outlook/precision-medicine>. It features all newly commissioned content as well as a selection of relevant previously published material.

All featured articles will be freely available for 6 months.

SUBSCRIPTIONS AND CUSTOMER SERVICES

Site licences (www.nature.com/libraries/site_licences): Americas, institutions@natureny.com; Asia-Pacific, <http://nature.asia/jp-contact>; Australia/New Zealand, nature@macmillan.com.au; Europe/ROW, institutions@nature.com; India, npindia@nature.com. Personal subscriptions: UK/Europe/ROW, subscriptions@nature.com; USA/Canada/Latin America, subscriptions@us.nature.com; Japan, <http://nature.asia/jp-contact>; China, <http://nature.asia/china-subscribe>; Korea, www.natureasia.com/ko-kr/subscribe.

CUSTOMER SERVICES

Feedback@nature.com

Copyright © 2016 Macmillan Publishers Ltd. All rights reserved.